Reports

Drug name	NICE TAs	Comments
Daratumumab	TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Hospital use only
Darbepoetin alfa (Aranesp)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323.
Daridorexant (QUVIVIQ®)		TA922: Daridorexant for treating long-term insomnia
Dasatinib tablets	TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia	Hospital use only
Deep Blue®		Lifting agent for use during complex EMR/ESD procedures
Deferiprone tablets (Ferriprox)		NHSE commissioned.
Degarelix injection	TA404 - Degarelix for treating advanced hormone-dependent prostate cancer	Supported by ESCA
Demeclocycline capsules		For the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone. Unlicensed.
Denosumab injection (Prolia®)	TA204 - Denosumab for the prevention of osteoporotic fractures in postmenopausal women	ESCA
Dermatonics Once Heel Balm®		Specialist recommendation for epidermolysis bullosa and diabetes patients only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports